Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr;67(2):79-88.
doi: 10.1007/s00005-018-0532-8. Epub 2018 Nov 15.

Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy

Arkadiusz Urbanowicz  1 , Radosław Zagożdżon  1   2   3 , Michał Ciszek  4
Affiliations
Review

Modulation of the Immune System in Chronic Hepatitis C and During Antiviral Interferon-Free Therapy

Arkadiusz Urbanowicz et al. Arch Immunol Ther Exp (Warsz). 2019 Apr.

Abstract

The treatment of patients with chronic hepatitis C virus (HCV) infection has changed tremendously over the past 2 years, with an increasing variety of all-oral direct-acting antiviral (DAA) treatment regimens available for different HCV genotypes and distinct clinical settings. These treatments have significantly improved safety in patients with advanced liver disease compared with interferon (IFN)-based regimens. HCV modifies the human immune system to escape immunosurveillance via several mechanisms. One of the basic mechanisms of HCV is the ability to "switch" the immune response by reducing the activity of cells responsible for the elimination of virus-infected cells. IFN-free DAA treatment regimens provide a unique opportunity to assess the effect of HCV elimination on the immune system. Abrupt changes in the immune system can in some cases be responsible for two alarming processes: viral reactivation in patients with chronic hepatitis B and recurrence of hepatocellular carcinoma in patients with previous successful cancer treatment.

Keywords: Direct-acting antivirals; HCV; Hepatocellular carcinoma; Immune system.

PubMed Disclaimer

References

    1. Abel M, Sene D, Pol S, et al. Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection. Hepatology. 2006;44:1607–1616. - PubMed
    1. Accapezzato D, Francavilla V, Paroli M, et al. Hepatic expansion of a virus-specific regulatory CD8(+) T cell population in chronic hepatitis C virus infection. J Clin Investig. 2004;113:963–972. - PMC - PubMed
    1. Aggeletopoulou I, Konstantakis C, Manolakopoulos S, et al. Risk of hepatitis B reactivation in patients treated with direct-acting antivirals for hepatitis C. World J Gastroenterol. 2017;23:4317–4323. - PMC - PubMed
    1. Ahlenstiel G, Titerence RH, Koh C. Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alpha-dependent manner. Gastroenterology. 2010;138:325.e1–2. - PMC - PubMed
    1. Aliannejad R, Ghanei M. Hepatitis C and pulmonary fibrosis: hepatitis C and pulmonary fibrosis. Hepat Mon. 2011;11:71–73. - PMC - PubMed